title: What's new in the antibiotic pipeline.
abstract: Many advances have recently been made in the development of chemotherapeutic agents for bacterial infections. As a consequence of problematic antimicrobial-resistant bacteria, research is now directed towards narrow-spectrum agents rather than broad-spectrum agents. Further, orally active agents have always been desirable, but today's cost-saving environment, in line with a desire to minimize treatment costs, values reduced administration costs and keeping patients out of the hospital. There has been a recent increase in research into orally active antibacterial agents, such as carbapenems and cephalosporins, and non-glycopeptide natural products.
authors.affiliation: Microcide Pharmaceuticals Inc. 850 Maude Avenue, Mountain View, CA 94043, USA. mailto:vingjlee@microcide.com.
authors.forename: V J
authors.initials: VJ
authors.lastname: Lee
authors.forename: G H
authors.initials: GH
authors.lastname: Miller
authors.forename: M
authors.initials: M
authors.lastname: Yagisawa
mesh_terms: D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000191:economics / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002986:Clinical Trials as Topic; D004352:Drug Resistance, Microbial; D006801:Humans
chemical_list: D000900:Anti-Bacterial Agents